Goldman Sachs
ARGS

Goldman Sachs’s Argos Therapeutics, Inc. ARGS Stock Holding History

Goldman Sachs’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,000
Closed -$245K – 7446
2016
Q2 		$245K Buy
+2,000
New +$267K ﹤0.01% 5525

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Goldman Sachs's ARGS Position: Q3 2017 in Review

Goldman Sachs sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 5,509 shares — an estimated $40K sold.

Goldman Sachs first reported a position in ARGS in Q2 2016 and held it in 4 quarters. The position peaked at $135K in Q3 2016. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Goldman Sachs reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 5,509 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $40K.
  • Goldman Sachs first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • Goldman Sachs's Argos Therapeutics, Inc. position peaked at $135K in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.